Andarine is categorized as non-steroidal Selective Androgen Receptor Modulator(SARM), exclusively restricted for preclinical laboratory research instead of approved human medication or clinical treatment worldwide. Its core research value roots in tissue-selective AR partial agonist activity, binding androgen receptor with Ki=4nM to activate anabolic signal inside skeletal muscle and bone cells while antagonizing excessive androgen stimulation within prostate tissue, which differs greatly from conventional synthetic anabolic steroids with systemic strong androgenic effects. Primary lab applications cover four core research directions. First, in-vivo animal modeling for osteoporosis pharmacology research; researchers establish ovariectomized rodent osteoporosis models to observe its efficacy on elevating bone mineral density and inhibiting bone resorption, exploring novel anti-osteoporotic candidate mechanism without prostate hyperplasia side effect of traditional testosterone drugs. Second, cachexia and muscle wasting disorder study, adopting tumor-bearing or starvation-induced muscle atrophy animal subjects to verify its function on conserving lean muscle mass and restraining progressive body weight loss for terminal disease-related wasting syndrome research. Third, benign prostatic hyperplasia(BPH) pharmacodynamic screening, investigating its anti-proliferation effect on prostate epithelial cells for new BPH drug development reference. Fourth, in-vitro cell-level AR pathway exploration, applied in mammalian muscle cell culture to analyze downstream protein synthesis regulation and androgen receptor conformational change mechanism. Strict global sport regulations classify Andarine as banned doping substance; human oral consumption for bodybuilding or athletic performance boost violates drug control and anti-doping laws in most nations.
GHS hazard classification marks Warning with H319 hazard statement for serious eye irritation, corresponding precaution codes P305+P351+P338 requiring abundant eye flushing with clean water once eye contact happens. For lab manual handling safety, wear full PPE including nitrile gloves, goggles and dustproof lab coat; avoid direct skin contact, inhalation of fine powder dust and accidental oral intake during weighing and solution preparation; all leftover solid waste and waste DMSO solution must be disposed via professional hazardous chemical treatment following local environmental regulation, prohibited for regular domestic trash discharge. From biological toxicology perspective, preclinical animal data proves multiple toxicity risks despite lacking complete long-term human toxicology data. The most typical adverse response is dose-dependent ocular toxicity: high-concentration administration triggers yellow-tinted vision, night blindness and intermittent visual flash via off-target binding on eye-related receptors, such symptoms turn reversible after substance discontinuation yet leave unknown long-term ocular damage risk. Moderate endogenous testosterone suppression emerges after continuous high-dose exposure, lowering natural androgen secretion and inducing fatigue, decreased libido and endocrine dysregulation in test subjects. Potential mild hepatotoxicity and cardiovascular burden are also recorded from relevant SARMs cohort research, with unclear long-term cardiac and hepatic cumulative toxicity boundary. Pregnancy and lactation-related toxicity remains unconfirmed via complete trials, so any cell/animal experiment involving maternal subjects strictly forbids compound dosing. Not FDA,EMA or NMPA approved for any human clinical indication, illegal human consumption for fitness violates pharmaceutical control policies across countries.
